

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065354 A1

(51) International Patent Classification⁷: **C07C 259/10**,
A61K 31/166, A61P 35/00

(21) International Application Number:
PCT/GB2004/000147

(22) International Filing Date: 19 January 2004 (19.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/440.616 17 January 2003 (17.01.2003) US

(71) Applicant (for all designated States except US):
TOPOTARGET UK LIMITED [GB/GB]; 87A Mil-
ton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FINN, Paul. W.**
[GB/GB]; TopoTarget UK Limited, 87A Milton Park,
Abingdon, Oxfordshire OX14 4RY (GB). **KALVINSH,**
Ivars [LV/LV]; Latvian Institute of Organic Synthesis,
Dept. of Medicinal Chemistry, Aizkraukles iela 21,
LV-1006 Riga (LV). **LOZA, Einars** [LV/LV]; Latvian
Institute of Organic Synthesis, Dept. of Medicinal
Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV).
GUTCAITS, Aleksandrs [LV/LV]; Latvian Institute
of Organic Synthesis, Dept. of Medicinal Chemistry,
Aizkraukles iela 21, LV-1006 Riga (LV). **OLUTNIKA,**
Irena [LV/LV]; Latvian Institute of Organic Synthesis,
Dept. of Medicinal Chemistry, Aizkraukles iela 21,
LV-1006 Riga (LV). **SERPIONOVA, Ludmila** [LV/LV];
Latvian Institute of Organic Synthesis, Dept. of Medicinal
Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV).
GAILITE, Vija [LV/LV]; Latvian Institute of Organic

Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela
21, LV-1006 Riga (LV). **BOKALDERE, Rasma** [LV/LV];
Latvian Institute of Organic Synthesis, Dept. of Medicinal
Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis, York
House, 23 Kingsway, London, Greater London WC2B 6HP
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS



(57) **Abstract:** This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity; wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or -C(=O)-; Cy is a cyclyl group and is independently: C₃₋₂₀carbocyclyl, C₃₋₂₀heterocyclyl, or C₅₋₂₀aryl; and is optionally substituted; Q¹ is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q² is an acid leader group, and is independently: C₁₋₈alkylene; and is optionally substituted; or: Q² is an acid leader group, and is independently: C₅₋₂₀arylene; C₅₋₂₀arylene-C₁₋₇alkylene; C₁₋₇alkylene-C₅₋₂₀arylene; or C₁₋₇alkylene-C₅₋₂₀arylene-C₁₋₇alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.